Briobacept (Research-Grade) is a research-grade biosimilar antibody targeting CD257. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Tumor necrosis factor ligand superfamily member 13B (CD257/BAFF) is a ~31 kDa protein. Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response.
Product Name:
Briobacept (Research-Grade)
SKU:
GXBS01193
Size:
100 µg, 1 mg
Target:
BAFF
Isotype:
Fusion - [TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)]2 - IGHG1 Fc (Fragment constant)
Reactivity:
Human
Applications:
ELISA, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
BR3-Fc, SS-79, 869881-54-9
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
